达巴万星一线治疗蜂窝织炎对入院人数和费用的影响:病例系列。

IF 3.7 3区 医学 Q2 INFECTIOUS DISEASES
{"title":"达巴万星一线治疗蜂窝织炎对入院人数和费用的影响:病例系列。","authors":"","doi":"10.1016/j.jgar.2024.05.020","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Many patients with cellulitis are treated with oral antibiotics as outpatients, but some require hospital admission for intravenous antibiotics. During the coronavirus disease 2019 pandemic, Betsi Cadwaladr University Health Board in Wales approved use of dalbavancin as first-line intravenous antibiotic from April to December 2020 to facilitate early discharge and prevent hospital admission.</p></div><div><h3>Objectives</h3><p>To report cost savings and admission avoidance through first-line intravenous use of dalbavancin for cellulitis in one health board in Wales.</p></div><div><h3>Patients and methods</h3><p>Patients with cellulitis who presented to the emergency department or medical assessment unit at Betsi Cadwaladr University Health Board's two hospitals between April and December 2020 were identified for treatment with dalbavancin, because they had not responded to oral antibiotics or their initial presentation warranted intravenous antibiotics. Patients received 1500 mg dalbavancin by intravenous infusion according to prescribing information and were sent home without being admitted. Outcomes were admission within 30 d of dalbavancin and cost savings from avoiding admission.</p></div><div><h3>Results</h3><p>31 patients were treated with dalbavancin for cellulitis in the emergency department or medical assessment unit. No patient was admitted within 30 d of receiving dalbavancin. Use of dalbavancin is estimated to have saved 248 bed-days over the study period, with an estimated saving of $120,444.23 based on avoidance of admission. The cost of dalbavancin for these 31 patients was $69,959.08, giving an overall cost saving of $50,485.15 ($1529.95 per patient).</p></div><div><h3>Conclusions</h3><p>Prescribing dalbavancin as first-line intravenous antibiotic for cellulitis prevents admission, saving bed-days and admission-related costs.</p></div>","PeriodicalId":15936,"journal":{"name":"Journal of global antimicrobial resistance","volume":null,"pages":null},"PeriodicalIF":3.7000,"publicationDate":"2024-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213716524001085/pdfft?md5=ff92a633f2c7cae31b370d140c2325ae&pid=1-s2.0-S2213716524001085-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Impact of first-line dalbavancin for cellulitis on hospital admissions and costs: A case series\",\"authors\":\"\",\"doi\":\"10.1016/j.jgar.2024.05.020\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Many patients with cellulitis are treated with oral antibiotics as outpatients, but some require hospital admission for intravenous antibiotics. During the coronavirus disease 2019 pandemic, Betsi Cadwaladr University Health Board in Wales approved use of dalbavancin as first-line intravenous antibiotic from April to December 2020 to facilitate early discharge and prevent hospital admission.</p></div><div><h3>Objectives</h3><p>To report cost savings and admission avoidance through first-line intravenous use of dalbavancin for cellulitis in one health board in Wales.</p></div><div><h3>Patients and methods</h3><p>Patients with cellulitis who presented to the emergency department or medical assessment unit at Betsi Cadwaladr University Health Board's two hospitals between April and December 2020 were identified for treatment with dalbavancin, because they had not responded to oral antibiotics or their initial presentation warranted intravenous antibiotics. Patients received 1500 mg dalbavancin by intravenous infusion according to prescribing information and were sent home without being admitted. Outcomes were admission within 30 d of dalbavancin and cost savings from avoiding admission.</p></div><div><h3>Results</h3><p>31 patients were treated with dalbavancin for cellulitis in the emergency department or medical assessment unit. No patient was admitted within 30 d of receiving dalbavancin. Use of dalbavancin is estimated to have saved 248 bed-days over the study period, with an estimated saving of $120,444.23 based on avoidance of admission. The cost of dalbavancin for these 31 patients was $69,959.08, giving an overall cost saving of $50,485.15 ($1529.95 per patient).</p></div><div><h3>Conclusions</h3><p>Prescribing dalbavancin as first-line intravenous antibiotic for cellulitis prevents admission, saving bed-days and admission-related costs.</p></div>\",\"PeriodicalId\":15936,\"journal\":{\"name\":\"Journal of global antimicrobial resistance\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2024-05-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2213716524001085/pdfft?md5=ff92a633f2c7cae31b370d140c2325ae&pid=1-s2.0-S2213716524001085-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of global antimicrobial resistance\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2213716524001085\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of global antimicrobial resistance","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213716524001085","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

摘要

背景:许多蜂窝组织炎患者在门诊接受口服抗生素治疗,但有些患者需要入院接受静脉注射抗生素治疗。在 2019 年冠状病毒疾病大流行期间,威尔士 Betsi Cadwaladr 大学卫生委员会(BCUHB)批准在 2020 年 4 月至 12 月期间使用达巴万星作为一线静脉注射抗生素,以促进尽早出院并避免入院治疗:报告威尔士一个卫生局通过一线静脉使用达巴万星治疗蜂窝组织炎而节省的成本和避免的入院情况:2020 年 4 月至 12 月期间,在 BCUHB 两家医院的急诊科 (ED) 或医疗评估室 (MAU) 就诊的蜂窝织炎患者被确定为达巴万星治疗对象,因为他们对口服抗生素无反应,或其初次就诊时需要静脉注射抗生素。患者根据处方信息通过静脉输注接受 1500 毫克达巴万星治疗,然后被送回家,无需住院。结果是患者在接受达巴万星治疗后 30 天内入院治疗,以及因避免入院治疗而节省的费用:31名蜂窝组织炎患者在急诊室或重症监护室接受了达巴万星治疗。没有患者在接受达巴万星治疗后 30 天内入院。据估计,在研究期间使用达巴万星可节省 248 个住院日,根据避免入院的情况计算,估计可节省 120,444.23 美元。这31名患者使用达巴万星的费用为69,959.08美元,总共节省了50,485.15美元(每位患者节省1,529.95美元):结论:将达巴万星作为静脉注射抗生素治疗蜂窝组织炎的一线用药可避免患者入院,从而节省住院日和入院相关费用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Impact of first-line dalbavancin for cellulitis on hospital admissions and costs: A case series

Background

Many patients with cellulitis are treated with oral antibiotics as outpatients, but some require hospital admission for intravenous antibiotics. During the coronavirus disease 2019 pandemic, Betsi Cadwaladr University Health Board in Wales approved use of dalbavancin as first-line intravenous antibiotic from April to December 2020 to facilitate early discharge and prevent hospital admission.

Objectives

To report cost savings and admission avoidance through first-line intravenous use of dalbavancin for cellulitis in one health board in Wales.

Patients and methods

Patients with cellulitis who presented to the emergency department or medical assessment unit at Betsi Cadwaladr University Health Board's two hospitals between April and December 2020 were identified for treatment with dalbavancin, because they had not responded to oral antibiotics or their initial presentation warranted intravenous antibiotics. Patients received 1500 mg dalbavancin by intravenous infusion according to prescribing information and were sent home without being admitted. Outcomes were admission within 30 d of dalbavancin and cost savings from avoiding admission.

Results

31 patients were treated with dalbavancin for cellulitis in the emergency department or medical assessment unit. No patient was admitted within 30 d of receiving dalbavancin. Use of dalbavancin is estimated to have saved 248 bed-days over the study period, with an estimated saving of $120,444.23 based on avoidance of admission. The cost of dalbavancin for these 31 patients was $69,959.08, giving an overall cost saving of $50,485.15 ($1529.95 per patient).

Conclusions

Prescribing dalbavancin as first-line intravenous antibiotic for cellulitis prevents admission, saving bed-days and admission-related costs.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of global antimicrobial resistance
Journal of global antimicrobial resistance INFECTIOUS DISEASES-PHARMACOLOGY & PHARMACY
CiteScore
8.70
自引率
2.20%
发文量
285
审稿时长
34 weeks
期刊介绍: The Journal of Global Antimicrobial Resistance (JGAR) is a quarterly online journal run by an international Editorial Board that focuses on the global spread of antibiotic-resistant microbes. JGAR is a dedicated journal for all professionals working in research, health care, the environment and animal infection control, aiming to track the resistance threat worldwide and provides a single voice devoted to antimicrobial resistance (AMR). Featuring peer-reviewed and up to date research articles, reviews, short notes and hot topics JGAR covers the key topics related to antibacterial, antiviral, antifungal and antiparasitic resistance.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信